LAZR vs. BOLT

Last updated Apr 2, 2026

Compare and contrast key facts about Luminar Technologies, Inc. (LAZR) and Bolt Biotherapeutics, Inc. (BOLT).

Performance

LAZR vs. BOLT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Luminar Technologies, Inc. (LAZR) and Bolt Biotherapeutics, Inc. (BOLT). The values are adjusted to include any dividend payments, if applicable.

LAZR vs. BOLT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
LAZR Luminar Technologies, Inc.	0.00%	-96.50%	-89.36%	-31.92%	-70.73%	-49.30%
BOLT Bolt Biotherapeutics, Inc.	-17.52%	-48.91%	-52.22%	-13.85%	-73.47%	-84.76%

Fundamentals

EPS LAZR : -$3.95 BOLT : -$17.54
PS Ratio LAZR : 0.15 BOLT : 1.11
Total Revenue (TTM) LAZR : $75.75M BOLT : $7.70M
Gross Profit (TTM) LAZR : -$16.13M BOLT : $7.93M
EBITDA (TTM) LAZR : -$161.26M BOLT : -$33.77M

Returns By Period

LAZR

• 1D: 0.00%
• 1M: 0.00%
• YTD: 0.00%
• 6M: -90.41%
• 1Y: -96.39%
• 3Y*: -87.54%
• 5Y*: -78.01%
• 10Y*: —

BOLT

• 1D: 11.63%
• 1M: -0.44%
• YTD: -17.52%
• 6M: -20.32%
• 1Y: -41.12%
• 3Y*: -45.46%
• 5Y*: -62.75%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

LAZR vs. BOLT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LAZR

LAZR Risk / Return Rank: 10
LAZR Sharpe Ratio Rank: 22
LAZR Sortino Ratio Rank: 9
LAZR Omega Ratio Rank: 6
LAZR Calmar Ratio Rank: 2
LAZR Martin Ratio Rank: 13

BOLT

BOLT Risk / Return Rank: 15
BOLT Sharpe Ratio Rank: 16
BOLT Sortino Ratio Rank: 18
BOLT Omega Ratio Rank: 19
BOLT Calmar Ratio Rank: 9
BOLT Martin Ratio Rank: 11

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LAZR vs. BOLT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Luminar Technologies, Inc. (LAZR) and Bolt Biotherapeutics, Inc. (BOLT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	LAZR	BOLT	Difference
Sharpe ratio Return per unit of total volatility	-0.41	-0.56	+0.15
Sortino ratio Return per unit of downside risk	-1.16	-0.55	-0.62
Omega ratio Gain probability vs. loss probability	0.82	0.94	-0.12
Calmar ratio Return relative to maximum drawdown	-0.99	-0.85	-0.14
Martin ratio Return relative to average drawdown	-1.36	-1.41	+0.05
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

LAZR vs. BOLT - Sharpe Ratio Comparison

The current LAZR Sharpe Ratio is -0.41, which is comparable to the BOLT Sharpe Ratio of -0.56. The chart below compares the historical Sharpe Ratios of LAZR and BOLT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	LAZR	BOLT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.41	-0.56	+0.15
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.59	-0.85	+0.25
Sharpe Ratio (All Time) Calculated using the full available price history	-0.53	-0.83	+0.30

Correlation

The correlation between LAZR and BOLT is 0.20, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

LAZR vs. BOLT - Dividend Comparison

Neither LAZR nor BOLT has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

LAZR vs. BOLT - Drawdown Comparison

The maximum LAZR drawdown since its inception was -99.97%, roughly equal to the maximum BOLT drawdown of -99.51%. Use the drawdown chart below to compare losses from any high point for LAZR and BOLT.

Drawdown Indicators

	LAZR	BOLT	Difference
Max Drawdown Largest peak-to-trough decline	-99.97%	-99.51%	-0.46%
Max Drawdown (1Y) Largest decline over 1 year	-96.31%	-51.25%	-45.06%
Max Drawdown (5Y) Largest decline over 5 years	-99.95%	-99.38%	-0.57%
Current Drawdown Current decline from peak	-99.97%	-99.44%	-0.53%
Average Drawdown Average peak-to-trough decline	-61.86%	-89.74%	+27.88%
Ulcer Index Depth and duration of drawdowns from previous peaks	71.21%	30.98%	+40.23%

Volatility

LAZR vs. BOLT - Volatility Comparison

The current volatility for Luminar Technologies, Inc. (LAZR) is 0.00%, while Bolt Biotherapeutics, Inc. (BOLT) has a volatility of 25.20%. This indicates that LAZR experiences smaller price fluctuations and is considered to be less risky than BOLT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	LAZR	BOLT	Difference
Volatility (1M) Calculated over the trailing 1-month period	0.00%	25.20%	-25.20%
Volatility (6M) Calculated over the trailing 6-month period	195.74%	54.35%	+141.39%
Volatility (1Y) Calculated over the trailing 1-year period	238.34%	73.47%	+164.87%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	133.12%	74.22%	+58.90%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	117.26%	75.14%	+42.12%

Financials